| Literature DB >> 35632596 |
Kerusha Govender1,2, Raveen Parboosing1, Salvatore Camiolo2, Petr Hubáček3, Irene Görzer4, Elisabeth Puchhammer-Stöckl4, Nicolás M Suárez2.
Abstract
Human cytomegalovirus (HCMV) can cause significant end-organ diseases such as pneumonia in HIV-exposed infants. Complex viral factors may influence pathogenesis including: a large genome with a sizeable coding capacity, numerous gene regions of hypervariability, multiple-strain infections, and tissue compartmentalization of strains. We used a whole genome sequencing approach to assess the complexity of infection by comparing high-throughput sequencing data obtained from respiratory and blood specimens of HIV-exposed infants with severe HCMV pneumonia with those of lung transplant recipients and patients with hematological disorders. There were significantly more specimens from HIV-exposed infants showing multiple HCMV strain infection. Some genotypes, such as UL73 G4B and UL74 G4, were significantly more prevalent in HIV-exposed infants with severe HCMV pneumonia. Some genotypes were predominant in the respiratory specimens of several patients. However, the predominance was not statistically significant, precluding firm conclusions on anatomical compartmentalization in the lung.Entities:
Keywords: HIV; compartmentalization; genotype; human cytomegalovirus; multiple-strain infections; pneumonia; whole genome sequence
Mesh:
Year: 2022 PMID: 35632596 PMCID: PMC9147013 DOI: 10.3390/v14050855
Source DB: PubMed Journal: Viruses ISSN: 1999-4915 Impact factor: 5.818
Patient data.
| Patient Code | Patient Location | Patient Diagnosis | Patient Age | HIV Status | Days Post-Transplant | Donor/Recipient HCMV Serostatus | Blood HCMV Load (Genome Copies/mL) | Respiratory HCMV Load (Genome Copies/mL) | Respiratory Specimen Type |
|---|---|---|---|---|---|---|---|---|---|
| DUR01 | South Africa | HIV-exposed infants with HCMV pneumonia a | 4 months | Negative | N/A | N/A | 48,600 | 11,615 | NBBAL |
| DUR02 | South Africa | 2 months | Negative | N/A | N/A | 26,487 | 10,230 | NBBAL | |
| DUR03 | South Africa | 4 months | Negative | N/A | N/A | 80,676 | 981,721 | NBBAL | |
| DUR04 | South Africa | 4 months | Positive | N/A | N/A | 71,199 | 2,019,329 | NBBAL | |
| DUR05 | South Africa | 2 months | Negative | N/A | N/A | 34,263 | 181,278 | NBBAL | |
| DUR06 | South Africa | 7 months | Positive | N/A | N/A | 7363 | 58,320 | NBBAL | |
| DUR07 | South Africa | 3 months | Positive | N/A | N/A | 58,806 | 84,564 | NBBAL | |
| DUR08 | South Africa | 3 months | Positive | N/A | N/A | 8942 | 63,909 | NBBAL | |
| DUR09 | South Africa | 2 months | Negative | N/A | N/A | 49,572 | 24,276 | NBBAL | |
| DUR10 | South Africa | 7 months | Positive | N/A | N/A | 32,562 | 132,435 | NBBAL | |
| DUR11 | South Africa | 3 months | Positive | N/A | N/A | 35,721 | 2,964,599 | NBBAL | |
| DUR12 | South Africa | 5 months | Positive | N/A | N/A | 826,200 | 777,600 | NBBAL | |
| PRA01 | Czech Republic | AML | 52 years | Negative | N/A | N/A | 5,900,000 | 867,500 | BAL |
| PRA02 | Czech Republic | HSCT | 62 years | Negative | 67 | D−/R+ | 246,500 | 55,250 | BAL |
| PRA03 | Czech Republic | HSCT | 58 years | Negative | 62 | D+/R+ | 133,000 | 672,500 | ETA |
| PRA04 | Czech Republic | HSCT | 21 years | Negative | 227 | D−/R+ | 5,537,500 | 893,750 | BAL |
| PRA05 | Czech Republic | MDS | 21 years | Negative | N/A | N/A | 903,750 | 785,000 | ETA |
| PRA06 | Czech Republic | Hyper IgM syndrome | 8 months | Negative | N/A | N/A | 20,750 | 198,500 | ETA |
| PRA07 | Czech Republic | HSCT | 58 years | Negative | 252 | D−/R+ | 56,750 | 980,000 | BAL |
| VIE04 | Austria | COPD | 49 years | Negative | 183 | D+R+ | 6630 | 55,400 | BAL |
| VIE06 | Austria | Pulmonary hypertension | 32 years | Negative | 169 | D+/R− | 11,300 | 1620 | BAL |
| VIE08 | Austria | COPD | 46 years | Negative | 187 | D−/R+ | 3390 | 3650 | BAL |
| VIE13 | Austria | Pulmonary fibrosis | 50 years | Negative | 206 | D−/R+ | 24,800 | 101,000 | BAL |
| VIE14 | Austria | COPD | 52 years | Negative | 219 | D+R+ | 16,400 | 132,000 | BAL |
| VIE15 | Austria | Pulmonary fibrosis | 43 years | Negative | 167 | D−/R+ | 18,100 | 62,200 | BAL |
| VIE16 | Austria | COPD | 56 years | Negative | 456 | D+R+ | 12,300 | 2380 | BAL |
| VIE17 | Austria | Alpha-1 antitrypsin deficiency | 54 years | Negative | 55 | D+R− | 1310 | 28,900 | BAL |
| VIE21 | Austria | COPD | 57 years | Negative | 185 | D+R− | 1200 | 11,900 | BAL |
| VIE24 | Austria | Bronchiectasis | 42 years | Negative | 176 | D+R+ | 35,800 | 134,000 | BAL |
a Those specimens with a volume greater than 500 μL and HCMV quantification at greater than 3.6 log IU/mL and 4 log IU/mL in blood and NBBAL, respectively, were selected for the present study (cut-off values defined previously (Govender et al. 2017)). AML, acute myeloid leukemia; HSCT, hematopoietic stem cell transplant; MDS, myelodysplastic syndrome; COPD, chronic obstructive pulmonary disease; N/A, not applicable; NBBAL, non-bronchoscopic bronchoalveolar lavage; BAL, bronchoalveolar lavage; ETA, endotracheal aspirate.
Difference in genotype prevalence between HIV-exposed infants with HCMV pneumonia, compared with patients with hematological disorders (HD) and lung transplant (LT) recipients.
| Gene Family/Function | Gene Locus | Genotype | Prevalence (%) | ||
|---|---|---|---|---|---|
| HIV-Exposed Infants | Patients with HD and LT Recipients | ||||
| RL11 family of membrane glycoproteins | UL9 | G4 | 10 (83.3%) | 5 (29.4%) | 0.008 |
| G8 | 4 (33.3%) | 0 (0.0%) | 0.021 | ||
| Glycoprotein B | UL55 | G2 | 8 (66.7%) | 2 (11.8%) | 0.005 |
| G5 | 4 (33.3%) | 0 (0.0%) | 0.021 | ||
| Glycoprotein N | UL73 | G4B | 5 (41.7%) | 0 (0.0%) | 0.007 |
| Glycoprotein O | UL74 | G4 | 5 (41.7%) | 0 (0.0%) | 0.007 |
| Glycoprotein M | UL100 | G2 | 9 (75.0%) | 3 (17.6%) | 0.006 |
| Membrane glycoprotein | UL120 | G4B | 7 (58.3%) | 2 (11.8%) | 0.014 |
Figure 1Heatmap showing distribution of genotypes between respiratory and blood specimens. The frequencies of reads are depicted for genotypes in respiratory and blood specimens of eleven patients with multiple-strain infection on a color scale, with darker shading in increments of 20%. MSI = multiple-strain infection. SSI = single-strain infection, B = blood; R = respiratory.
Genotypes more predominant in respiratory specimens.
| Gene Family/Function | Gene | Genotype | Patients with a Predominance of This Genotype in the Respiratory Specimen |
|---|---|---|---|
| RL11 family of membrane glycoproteins | RL13 | G1 | PRA02, PRA03, DUR03, DUR04, DUR05, DUR09, DUR11 |
| UL1 | G1 | PRA03, DUR02, DUR03, DUR04, DUR05, DUR09, DUR11 | |
| UL9 | G4 | PRA03, DUR02, DUR03, DUR04, DUR05, DUR09 | |
| UL11 | G1 | PRA01, PRA02, PRA03, DUR03, DUR09, DUR11 | |
| Glycoprotein H | UL75 | G1 | PRA01, PRA03, DUR02, DUR03, DUR04, DUR07, DUR09, DUR11 |
| Glycoprotein M | UL100 | G1 | PRA02, PRA03, DUR02, DUR04, DUR05, DUR11, VIE15 |